Skip to Content

Tenax Therapeutics Inc TENX

Morningstar Rating
$3.42 +0.10 (3.01%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

TENX is trading at a 513% premium.
Price
$3.46
Fair Value
$1.38
Uncertainty
Extreme
1-Star Price
$71.80
5-Star Price
$6.75
Economic Moat
Ffyl
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TENX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$3.32
Day Range
$3.293.42
52-Week Range
$2.7761.20
Bid/Ask
$3.29 / $3.49
Market Cap
$6.70 Mil
Volume/Avg
7,644 / 23,696

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
5

Valuation

Metric
TENX
Price/Earnings (Normalized)
Price/Book Value
0.54
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
TENX
Quick Ratio
6.18
Current Ratio
7.12
Interest Coverage
−406.91
Quick Ratio
TENX

Profitability

Metric
TENX
Return on Assets (Normalized)
−73.22%
Return on Equity (Normalized)
−83.14%
Return on Invested Capital (Normalized)
−79.67%
Return on Assets
TENX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
WkzqzqdwwCgrs$589.6 Bil
Vertex Pharmaceuticals Inc
VRTX
XyyvvybmbTgszc$126.9 Bil
Regeneron Pharmaceuticals Inc
REGN
QsgbgpmkFvsdt$117.2 Bil
Moderna Inc
MRNA
QrtcxgwRtfd$46.4 Bil
Alnylam Pharmaceuticals Inc
ALNY
WwbxghyRtdrrdm$30.1 Bil
argenx SE ADR
ARGX
ZcjylmzlmDrz$27.8 Bil
BioNTech SE ADR
BNTX
PdyzmcmfjGfgv$20.6 Bil
Biomarin Pharmaceutical Inc
BMRN
TmxylgqwFhlhft$16.0 Bil
United Therapeutics Corp
UTHR
CwkbspdWcmlt$14.6 Bil
Incyte Corp
INCY
FtdkzpfBpqycbq$13.0 Bil

Sponsor Center